Related Experiment Video
Updated: Jun 25, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Disrupting Redox Balance: A Redox-Based Strategy to Combat Temozolomide Resistance in Glioblastoma
Asuman Celebi1, Turker Kilic2, Timucian Avsar1
1Medical Biology Department, Faculty of Medicine, Bahçeşehir University, Istanbul, Turkey.
Introduction:
Glioblastoma is an aggressive brain tumor with a median survival of only 15 months despite current therapies. Temozolomide (TMZ) is the standard chemotherapeutic due to its ability to cross the blood-brain barrier; however, acquired resistance limits its efficacy. Oxidative stress, particularly the regulation of Reactive Oxygen Species (ROS), has a dual role in tumor progression and cell death. Cancer cells tightly balance ROS through antioxidant systems fueled by NADPH, which is generated by NADK enzymes, while NADPH oxidases (NOX) produce ROS. Here, the study investigated whether disrupting NADPH homeostasis could enhance oxidative stress and induce cytotoxicity in TMZ-resistant glioblastoma.
Materials And Methods:
The study investigated the effects of Thionicotinamide (TIO) and Sanguinarine (SNG), a NADK2 inhibitor and a NOX5 activator, on cell viability, gene expression, ROS and NADPH levels, apoptosis, and colony formation in glioma cell lines and healthy control HUVECs. Cells were treated for 24 hours with sub-toxic concentrations of SNG (0.5 µM) and TIO (100 µM).
Results:
Combined SNG and TIO treatment significantly reduced viability in TMZ-resistant cells (LN18 and TMZresU87-MG), but not in TMZ-sensitive or control cells. Intracellular ROS levels doubled in resistant cells after combined treatment, while NADPH levels decreased 20% in both resistant and sensitive glioma cells. Gene expression analysis revealed that TIO reduced NADK2 expression, and SNG upregulated NOX5 in TMZresistant cells.
Discussion:
These findings suggest that lowering NADPH levels (a necessary catalyst for the cell) and increasing ROS disrupted the cellular homeostasis. Increased oxidative stress in the cell is particularly pronounced in TMZ-resistant cells.
Conclusion:
This study provides evidence that co-targeting ROS production and NADPH depletion using SNG and TIO synergistically induces oxidative stress and cytotoxicity in TMZ-resistant glioma, highlighting a promising strategy for overcoming TMZ resistance.
Insights
Targeting NADPH and ROS pathways with Sanguinarine (SNG) and Thionicotinamide (TIO) effectively combats temozolomide-resistant glioblastoma. This combination therapy enhances oxidative stress and induces cancer cell death, offering a new strategy against aggressive brain tumors.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Glioblastoma is an aggressive brain tumor with poor prognosis.
- Temozolomide (TMZ) resistance is a major clinical challenge.
- NADPH homeostasis and Reactive Oxygen Species (ROS) play critical roles in cancer cell survival and death.
Purpose of the Study:
- To investigate if disrupting NADPH homeostasis can enhance oxidative stress and induce cytotoxicity in TMZ-resistant glioblastoma.
- To evaluate the combined effects of a NADK2 inhibitor (Thionicotinamide, TIO) and a NOX5 activator (Sanguinarine, SNG).
Main Methods:
- Glioma cell lines and HUVECs were treated with sub-toxic concentrations of SNG (0.5 µM) and TIO (100 µM).
- Assessed cell viability, gene expression (NADK2, NOX5), ROS and NADPH levels, apoptosis, and colony formation.
- Utilized TMZ-resistant and TMZ-sensitive cell lines.
Main Results:
- Combined SNG and TIO treatment significantly reduced viability in TMZ-resistant glioblastoma cells.
- Intracellular ROS levels doubled, while NADPH levels decreased in resistant cells.
- TIO reduced NADK2 expression, and SNG upregulated NOX5 in TMZ-resistant cells.
Conclusions:
- Disrupting NADPH homeostasis and increasing ROS synergistically induces oxidative stress and cytotoxicity.
- Co-targeting ROS production and NADPH depletion presents a promising strategy to overcome TMZ resistance in glioblastoma.
- This approach highlights a potential new therapeutic avenue for aggressive brain tumors.
Related Concept Videos
02:56Treatment Resistant Cancers
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...